Trending NewsTrending NewsNASDAQ:MRNA Moderna (MRNA) Stock Price, News & Analysis $200.61 +1.28 (+0.64%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Moderna Stock (NASDAQ:MRNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moderna alerts:Sign Up Key Stats Today's Range$196.50▼$210.0050-Day Range$143.77▼$269.0052-Week Range$22.28▼$280.80Volume4.14 million shsAverage Volume12.45 million shsMarket Capitalization$81.17 billionP/E RatioN/ADividend YieldN/APrice Target$120.25Consensus RatingHold Company Overview Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts. Its products and development programs serve markets in the United States and internationally.AI Generated. May Contain Errors. Read More Moderna Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreMRNA MarketRank™: 1.368884002195 of 5 starsModerna scored higher than 27% of companies evaluated by MarketBeat, and ranked 757th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingModerna has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 6 buy ratings, 15 hold ratings, and 4 sell ratings.Downside RiskModerna has a consensus price target of $120.25, representing about 39.7% downside from its current price of $199.33.Amount of Analyst CoverageModerna has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Moderna's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moderna are expected to grow in the coming year, from ($5.40) to ($3.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moderna is -28.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moderna is -28.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioModerna has a P/B Ratio of 11.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.32% of the float of Moderna has been sold short.Short Interest Ratio / Days to CoverModerna has a short interest ratio ("days to cover") of 1.76, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moderna has recently increased by 1.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldModerna does not currently pay a dividend.Dividend GrowthModerna does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.26 News SentimentModerna has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 36 news articles for Moderna this week, compared to 9 articles on an average week.Search InterestOnly 67 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat FollowsOnly 23 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is a decrease of -41% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,776,076.00 in company stock.Percentage Held by Insiders10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Moderna's insider trading history. Receive MRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRNA Stock News HeadlinesModerna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,160 SharesNovember 20 at 4:08 AM | americanbankingnews.comModerna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027November 20 at 3:55 AM | fool.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 20 at 1:00 AM | Porter & Company (Ad)Moderna (NASDAQ:MRNA) Stock Crosses Below 50 Day Moving Average on Insider SellingNovember 20 at 2:16 AM | americanbankingnews.comModerna (NASDAQ:MRNA) President Sells $8,298,286.15 in StockNovember 19 at 6:22 AM | insidertrades.comThe AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom (MRNA)AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology...November 11, 2026 | marketbeat.comMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.October 27, 2026 | marketbeat.comMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid?Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.October 27, 2026 | marketbeat.comSee More Headlines MRNA Stock Analysis - Frequently Asked Questions How have MRNA shares performed this year? Moderna's stock was trading at $29.49 at the beginning of the year. Since then, MRNA shares have increased by 575.9% and is now trading at $199.33. How were Moderna's earnings last quarter? Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings results on Friday, November, 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $1.48. The business's quarterly revenue was up 29.2% compared to the same quarter last year. Read the conference call transcript. When did Moderna IPO? Moderna (MRNA) raised $604 million in an initial public offering on Friday, December 7th 2018. The company issued 26,275,993 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers. Who are Moderna's major shareholders? Moderna's top institutional shareholders include State Street Corp (3.82%), Theleme Partners LLP (1.65%), Banque Pictet & Cie SA (0.54%) and Bamco Inc. NY (0.34%). Insiders that own company stock include Stephen Hoge, Shannon Thyme Klinger, James M Mock, Abbas Hussain, Noubar Afeyan and Arpa Garay. View institutional ownership trends. How do I buy shares of Moderna? Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moderna own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), NIO (NIO), Alibaba Group (BABA) and PayPal (PYPL). Company Calendar Last Earnings11/06/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MRNA's financial health is in the Green zone, according to TradeSmith. MRNA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MRNA CIK1682852 Webwww.modernatx.com Phone(617) 714-6500FaxN/AEmployees4,700Year Founded2010Price Target and Rating Average Price Target for Moderna$120.25 High Price Target$305.00 Low Price Target$17.00 Potential Upside/Downside-41.2%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($7.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.82 billion Net Margins-110.46% Pretax Margin-108.08% Return on Equity-25.79% Return on Assets-15.85% Debt Debt-to-Equity Ratio0.52 Current Ratio3.62 Quick Ratio3.47 Sales & Book Value Annual Sales$1.94 billion Price / Sales42.59 Cash FlowN/A Price / Cash FlowN/A Book Value$16.90 per share Price / Book12.11Miscellaneous Outstanding Shares404,620,000Free Float360,922,000Market Cap$82.80 billion OptionableOptionable Beta1.16 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MRNA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredI'm handing you this one freeDylan has tracked down the company behind what he calls the StarChip. It's already inside more than 10,000 Sta...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.